Computed tomography (CT) or magnetic resonance imaging (MRI) scan must be obtained within  weeks prior to study entry
Patients must have shown unequivocal radiographic evidence for tumor progression by magnetic resonance imaging (MRI) or computed tomography (CT) scan; if an MRI is being obtained to verify eligibility, it is recommended that the MRI parameters follow the specifications detailed in the protocol so that the patient will not require a repeat MRI prior to treatment start
Participants with known brain metastases may be enrolled in this study if radiation therapy and/or surgery have been completed with a minimum of  months of stable disease demonstrated on serial evaluation by computed tomography (CT) (with contrast enhancement) or magnetic resonance imaging (MRI); such participants must no longer require treatment with corticosteroids or enzyme inducing anti-epileptic medications for their central nervous system (CNS) disease
Have undergone magnetic resonance imaging (MRI) for MB, a computerized tomography (CT) / metaiodobenzylguanidine (MIBG) scan for NB, and CT / magnetic resonance imaging (MRI) for ES or ARMS within  month prior to first dose of study treatment
Magnetic resonance imaging (MRI) (or computed tomography [CT] if MRI contraindicated) within  days prior to start of study drug; corticosteroid dose must be stable or decreasing for at least  days prior to the scan; if steroids are added or the steroid dose is increased between the date of the screening MRI or CT scan and the start of treatment, a new baseline MRI or CT is required
Patients must have an unequivocal progression by magnetic resonance imaging (MRI) or computed tomography (CT) scan; a scan must be performed within  days prior to registration and on a steroid dose that has been stable or decreasing for at least  days; if the steroid dose is increased between the date of imaging and initiation of study treatment, a new baseline MRI/CT is required
Post-operative computed tomography (CT) myelogram or magnetic resonance imaging (MRI) perfusion with evidence of separation of tumor and the spinal cord
Hepatocellular carcinoma (HCC) diagnosed either by histology/pathology or Liver Imaging Reporting and Data System (LIRADs  per the American College of Radiology [ACRs] LIRADs criteria) by computed tomography (CT) or magnetic resonance imaging (MRI)
Has  or more discrete malignant lesions that are amenable to ? separate biopsies guided by one of the following modalities: visual inspection, ultrasound guidance, or cross sectional image guidance (computed tomography/magnetic resonance imaging [CT/MRI]).
Must be able to tolerate computed tomography (CT) and/or magnetic resonance imaging (MRI) with contrast
Locally advanced HCC as defined by: ) tissue diagnosis OR ) alpha-fetoprotein (AFP) >  ng/mL with compatible mass on contrast-enhanced imaging OR ) compatible mass on dual phase computed tomography (CT) or dynamic contrast enhanced magnetic resonance imaging (MRI) demonstrating both arterial hypervascularity and delayed washout
Tumor thickness is  mm or less (measured clinically and/or by computed tomography [CT] or magnetic resonance imaging [MRI] scan)
Patients who cannot undergo neither MRI nor computed tomography (CT) evaluation/examination
At least one lesion that can be accurately assessed at baseline by computed tomography (TC), magnetic resonance imaging (MRI) or X-ray, that is suitable for repeated measurement, OR
Patients with known central nervous system metastases may be enrolled if they have received radiotherapy, do not require chronic steroid therapy, have had computed tomography or magnetic resonance imaging of the brain within  month of study entry that shows stable disease and they have no neurological symptoms other than low grade neuropathy.
Must be found to have locally advanced unresectable disease following standard chemotherapy and/or (+/-) radiotherapy as demonstrated with computed tomography (CT)/magnetic resonance imaging (MRI) and surgical evaluation
ARM I&II: Patients must have gadolinium magnetic resonance imaging (MRI) or contrast computed tomography (CT) with contrast within  days prior to starting treatment
Six or more metastases on diagnostic or treatment planning imaging, which include either computed tomography (CT) or magnetic resonance (MR) imaging.
Histologically confirmed metastatic uveal melanoma in the liver; patients must have at least one measurable liver metastasis that is ?  mm in longest diameter by spiral computed tomography (CT) scan or magnetic resonance imaging (MRI); the total volume of the tumors must be less than % of the liver volume
Metastatic disease evident on computed tomography (CT) or magnetic resonance imaging (MRI) staging scans
Centrally located tumors with radiographic evidence (computed tomography [CT] or magnetic resonance imaging [MRI]) of local invasion of major blood vessels
Patients with central nervous system (CNS) progression (parenchymal but not leptomeningeal) are eligible if CNS metastases are treated and deemed stable (with a repeat computed tomography [CT]/magnetic resonance imaging [MRI] imaging study) prior to the enrollment date; if radiation is used to treat CNS parenchymal disease, a  week washout period will apply
Unequivocal evidence of progressive disease on contrast-enhanced brain computed tomography (CT) or magnetic resonance imaging (MRI) as defined by Response Assessment in Neuro-Oncology (RANO) criteria, or have documented recurrent glioma on diagnostic biopsy
Patients with a parenchymal brain lesion thought to be consistent with active lymphoma on screening computed tomography/magnetic resonance imaging (CT/MRI); of note, patients with cerebral spinal fluid (CSF) involvement alone are not excluded
Patients must have imaging (magnetic resonance imaging [MRI] or computed tomography [CT] abdomen liver protocol) confirmed hepatocellular carcinoma. Patients cannot have metastatic HCC
Gross disease apparent on imaging (magnetic resonance imaging [MRI] or computed tomography [CT])
Patients must have demonstrated evidence of increasing contrast enhancement on MR or computed tomography (CT) imaging while on stable or increasing dose of steroid
The primary tumor must be measurable by an imaging modality prior to treatment; this imaging modality is to be repeated after completion of  cycles of paclitaxel and prior to surgery; such imaging modalities may include ultrasound, computed tomography (CT), mammography, or magnetic resonance imaging (MRI); MRI will be the preferred imaging modality if available; all imaging will be performed per standard of care at the discretion of the treating physicians
COHORT  (ON PROGRESSION OF SORAFEINIB): Patients who have received prior sorafenib therapy for at least  weeks and has confirmation of disease progression on computed tomography/magnetic resonance imaging (CT/MRI); prior surgery or local therapy within  weeks prior to cycle  day , with the exception of palliative radiation therapy to the bone
Known active metastases to the brain, spinal cord or leptomeninges unless adequately treated with radiotherapy, radiosurgery, or surgery and stable for at least  weeks of first study treatment as documented by magnetic resonance imaging (MRI) or computerized tomography (CT) imaging and having no ongoing requirement for steroids
Clinical stage T or less as demonstrated by computed tomography (CT)/magnetic resonance imaging (MRI) will be selected as the prostate is resectable
Locally advanced rectal cancer determined by any of the following features\r\n* Fixed or immobile tumor on physical exam and/or\r\n* T disease with invasion through the muscularis propria as defined by transrectal ultrasound, computed tomography (CT) or magnetic resonance imaging (MRI)\r\n* T disease with invasion of adjacent structures such as pelvic sidewall, sacrum, pelvis, bladder and/or prostate as determined appropriate imaging modalities such as ultrasound, CT or MRI\r\n* Any T with + N on CT scan/MRI or transrectal ultrasound
Patients must have potentially resectable pancreatic carcinoma and have agreed to undergo surgical resection at Monroe Dunaway (MD) Anderson Cancer Center if operable; they will have undergone staging (physical examination, contrast enhanced computed tomography [CT] or magnetic resonance imaging [MRI] [if CT contraindicated] to determine resectability)
Unable to tolerate a contrast enhanced computed tomography (CT) or magnetic resonance imaging (MRI) for staging/restaging purposes
No evidence of metastasis on computed tomography (CT) or magnetic resonance imaging (MRI) of the pelvis within  days prior to registration
All patients positive for invasion must have imaging (computed tomography [CT] scan or magnetic resonance imaging [MRI]) documenting normal upper urinary tracts and absence of locally advanced bladder cancer within  days prior to study registration
Patients unable to have IV contrast for computed tomography (CT) and MRI imaging
Patients must be willing to undergo a radiologic scan (computed tomography [CT] or magnetic resonance imaging [MRI], depending on organ involved) after last drug dose and prior to minimally-invasive surgery
Preoperative evaluation to rule-out extra-uterine disease may include computed tomography (CT) scan, magnetic resonance imaging (MRI), or ultrasound; preoperative imaging is not mandatory for study enrollment
At screening, patients with =<  untreated central nervous system (CNS) metastases may be included provided none of the untreated lesions are >  cm in greatest dimension, and there is no peri-tumoral edema present on brain imaging (magnetic resonance imaging [MRI] or computed tomography [CT] if MRI is contraindicated), and if the patients with CNS metastases are not taking prednisone >  mg or equivalent daily
No evidence of > grade  active CNS hemorrhage on the baseline magnetic resonance imaging (MRI) or computed tomography (CT) scan
Localized spine metastasis from the cervical (C) to lumbar (L) levels with documented epidural cord compression by a screening imaging study (magnetic resonance imaging [MRI] or computed tomography [CT] myelogram); site may have a maximal involvement of  contiguous vertebral bodies; patients with other visceral metastasis, and radioresistant tumors (including soft tissue sarcomas, melanomas, and renal cell carcinomas) are eligible
Participants must be diagnosed with HCC either pathologically or by the American Association for the Study of Liver Diseases (AASLD) radiographic criteria; the criteria specifies computed tomography (CT) or magnetic resonance imaging (MRI) intense arterial uptake followed by washout of contrast in the venous-delayed phases; any atypical lesions must be confirmed by biopsy
Patients must have at least one measurable lesion that can be accurately measured with spiral computed tomography (CT) scan, magnetic resonance imaging (MRI) scan, or physical exam (by calipers only); (PTCL, AITL and follicular lymphoma patients will be assessed on this study using the Lugano criteria for the evaluation of lymphomas; CTCL and MF patients will be assessed using International Society for Cutaneous Lymphomas [ISCL] and European Organization for Research and Treatment of Cancer [EORTC criteria])
Patients must have a diagnosis of hepatocellular carcinoma by at least one criterion listed below:\r\n* Histologically confirmed\r\n* Magnetic resonance imaging (MRI) or computerized tomography (CT) findings consistent with hepatocellular carcinoma\r\n* Alpha fetoprotein (AFP) >  ng/mL AND evidence of at least one solid liver lesion >  cm regardless of specific imaging characteristics on CT or MRI
Subjects must be able to undergo either MRI or computed tomography (CT)
Adult patients with locally advanced or recurrent orbital or periorbital BCCA, or a medial canthal BCCA that threatens the lacrimal drainage system, as noted by clinical exam, clinical photography, computed tomography (CT) or magnetic resonance imaging (MRI) and positive biopsy, and who do not have a contraindication to either surgical or vismodegib treatment\r\n* Treating physician to assess whether the patient is a candidate for vismodegib treatment
Clinically confirmed brain metastases by computed tomography (CT) or magnetic resonance imaging (MRI) criteria; if there is evidence of extra-cranial metastatic disease, it is preferable if that the lesions be pathologically confirmed and reviewed by a University of Utah or Huntsman Cancer Hospital pathologist if the initial review was done at an outside facility
Patients may not be on systemic steroids within  weeks of enrolling on study with the exception of physiologic replacement doses (for instance in the case of adrenal insufficiency) or steroid premedication for baseline magnetic resonance imaging (MRI) and/or computed tomography (CT) in the case of subjects with known contrast dye allergies
Visceral metastases as assessed by abdominal or pelvic computed tomography (CT) or other imaging modality
Centrally located tumors with radiographic evidence (CT or magnetic resonance imaging [MRI]) of local invasion of major blood vessels
No pelvic nodal metastases (based on computed tomography [CT] or magnetic resonance imaging [MRI] findings)
Known leptomeningeal disease or evidence of prior or current metastatic brain disease (routine screening with central nervous system [CNS] imaging studies [computed tomography (CT) or magnetic resonance imaging (MRI)] is required only if clinically indicated)
Must have presence of an enhancing solid renal mass =< . cm on computed tomography (CT) or magnetic resonance imaging (MRI)
Clinically negative lymph nodes as established by imaging (pelvic  abdominal computed tomography [CT] or magnetic resonance imaging [MRI]), (but not by nodal sampling, or dissection) within  days prior to registration
Pancreas protocol computed tomography (CT) and/or magnetic resonance imaging (MRI) if required for further clarification of disease tissue planes within  weeks of registration
Contraindication to both contrast enhanced magnetic resonance imaging (MRI) and contrast enhanced computed tomography (CT) (i.e. unable to undergo follow-up imaging or SBRT treatment planning)
Participants must have histologically or radiological evidence of stage I (TNM) renal cell carcinoma with a size no larger than  cm in greatest dimension measured by magnetic resonance imaging (MRI) or computed tomography (CT) scan
Contrast computed tomography (CT) and/or magnetic resonance imaging (MRI) of the brain negative for central nervous system metastases within  days of treatment
Magnetic resonance imaging (MRI) with gadolinium should be obtained within  days prior to beginning treatment; patients without measurable disease are eligible; participants must be able to undergo MRIs (computed tomography scans [CTs] are not allowed for response assessment on study)
At least one measurable viable tumor in the liver, ? cm longest diameter (LD), using a dynamic imaging technique (arterial phase of triphasic computerized tomography [CT] scan, or dynamic contrast-enhanced magnetic resonance imaging [MRI]), and injectable under imaging-guidance (CT and/or ultrasound)
Patients must have an magnetic resonance imaging (MRI) or computed tomography (CT) of the head showing no central nervous system (CNS) metastases within  weeks of study entry
Confirmed presence of hepatocellular carcinoma indicated on computed tomography, magnetic resonance, or other imaging techniques within  months prior to screening
High-quality cross-sectional imaging (computed tomography [CT] or magnetic resonance imaging [MRI]) performed within  weeks prior to enrollment
Clinical TNM (=<  cm) renal mass as measured on cross-sectional imaging (computed tomography [CT] or magnetic resonance imaging [MRI])
Active and untreated central nervous system (CNS) metastasis (including metastasis identified during screening magnetic resonance imaging [MRI] or contrast computed tomography [CT]).
All patients must have measurable disease by imaging defined as tumor that can be measured >=  mm with multiparametric magnetic resonance imaging (MRI) (primary modality of imaging) or computed tomography (CT) (as an alternative) or >=  mm by caliper on physical examination
Patients must have localized disease with a primary tumor >=  cm by magnetic resonance imaging (MRI) or computed tomography (CT) scan
Symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression as documented by computed tomography (CT) or magnetic resonance imaging (MRI) scan, analysis of cerebrospinal fluid or neurological exam; patients with primary glioblastoma multiforme are excluded
Have been more than  month and less than  months after the completion of planned adjuvant chemotherapy and no definitive evidence of recurrent disease on screening imaging (computed tomography [CT] or magnetic resonance imaging [MRI]); if adjuvant treatment is not planned, then patients must be more than  month and less than  months after resection of their pancreas cancer
Computed tomography (CT) or magnetic resonance imaging (MRI) within  days prior to start of study therapy
Patients must be able to tolerate computed tomography (CT), magnetic resonance imaging (MRI) or PET imaging including contrast agents
Known contraindication to enhanced magnetic resonance imaging (MRI) and computed tomography (CT) scan
Solid tumor patients must be off corticosteroids prior to registration; if GBM patient is receiving corticosteroids, patient must be on a stable or decreasing dose of corticosteroids for at least  days prior to baseline magnetic resonance imaging (MRI) or computed tomography (CT); if steroids are added or the steroids dose is increased between the date of the screening MRI or CT and the start of treatment, a new baseline MRI or CT is required
Histologically confirmed cancer with measurable or evaluable brain metastases by computed tomography (CT) or magnetic resonance imaging (MRI); MRI is preferred, but a CT scan is acceptable for patients that are unable to have an MRI
Computerized tomography (CT) urogram or magnetic resonance imaging (MRI) urogram; if urogram protocol not available or contrast allergy/poor renal function preclude such imaging, then noncontrast CT or MRI of the abdomen/pelvis within  days of study entry will suffice
Unresectable by radiographic criteria (pancreas protocol computed tomography [CT] or magnetic resonance imaging [MRI]) or exploration within  days prior to registration
At screening, patients with =<  untreated central nervous system (CNS) metastases may be included provided none of the untreated lesions are >  cm in greatest dimension, and there is no peri-tumoral edema present on brain imaging (magnetic resonance imaging [MRI] or computed tomography [CT] if MRI is contraindicated)
At screening, patients with =<  untreated central nervous system (CNS) metastases may be included provided none of the untreated lesions are >  cm in greatest dimension, and there is no peri-tumoral edema present on brain imaging (magnetic resonance imaging [MRI] or computed tomography [CT] if MRI is contraindicated)
Any lesion invading or having encasement ?  degrees around the wall of a major blood vessel as assessed by computed tomography (CT) scan and/or magnetic resonance imaging (MRI).
Computed tomography (CT), magnetic resonance imaging (MRI) or ultrasound of the abdomen and chest; required only if aspartate aminotransferase (AST)/alanine aminotransferase (ALT) or ALP is ? x ULN
>= % surgical resection of recurrent GBM confirmed by central radiology review by magnetic resonance imaging (MRI) with or without gadolinium per institutional guidelines; a computed tomography (CT) scan is allowable in place of MRI only in situations where an MRI is contraindicated (e.g., patient has a heart pacemaker, metallic devices in the eye, brain or spine, severe claustrophobia)
Active or untreated central nervous system (CNS) metastases as determined by computed tomography (CT) or magnetic resonance imaging (MRI) evaluation
Able to undergo repeated magnetic resonance imaging (magnetic resonance imaging (MRI), computed tomography (CT) scans).
Centrally located tumors with radiographic evidence (CT or magnetic resonance imaging [MRI]) of local invasion of major blood vessels
Known presence of the brain or spinal cord metastasis, as determined by computed tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening or prior radiographic assessments
Pathologic (histologically or cytologically) documented extracranial diagnosis of primary lung cancer, melanoma, human epidermal growth factor receptor  (HER)-amplified or immuno-positive breast cancer, or HER-amplified or immuno-positive gastric cancer, with brain metastasis detected by contrast enhanced magnetic resonance imaging (MRI) or computed tomography (CT) is required; patients with concurrent leptomeningeal diseases are eligible
Unwilling or unable to undergo a magnetic resonance imaging (MRI) or computed tomography (CT) scan
Known leptomeningeal involvement by lymphoma or current metastatic brain disease; routine screening with central nervous system (CNS) imaging studies (computed tomography [CT] or magnetic resonance imaging [MRI]) is required only if clinically indicated
Patients with stage IV malignancy (non-mesothelioma) must have had a brain scan (magnetic resonance imaging [MRI] or computed tomography [CT] with contrast) showing no evidence of disease progression within  weeks of study enrollment
To differentiate T lesions involving the mediastinal pleura from T lesions involving major vessels or organs, a chest magnetic resonance imaging (MRI) will be obtained; if any uncertainty remains, the patient will have four-dimensional computed tomography (CT) scans (DCT) in an effort to determine the degree of tumor motion; a freely mobile tumor during ventilation will be judged to be T disease
Complete clinical remission is defined as cancer antigen (CA)- within normal limits, examination and computed tomography (CT) or magnetic resonance imaging (MRI) without objective evidence of disease (non specific abnormalities are permitted on radiologic imaging)
No centrally located tumors with radiographic evidence (CT or magnetic resonance imaging [MRI]) of local invasion of major blood vessels
Histologically confirmed diagnosis of adenocarcinoma of the prostate within  weeks prior to registration at very high risk of recurrence as determined by  or more of the following combinations:\r\n* cTa/b\r\n* PSA >= \r\n* Gleason score -\r\n* >= % core involvement\r\n* OR any patient with pelvic lymph node involvement >=  cm as determined by pelvic computed tomography (CT) or magnetic resonance imaging (MRI) imaging will meet eligibility criteria for enrollment
Patients with known or suspected brain metastases; however, if radiation therapy and/or surgery has been completed and serial evaluation by computed tomography (CT) (with contrast enhancement) or magnetic resonance imaging (MRI) over a minimum of  months demonstrates the disease to be stable and if the patient remains asymptomatic, then the patient may be enrolled; such patients must have no need for treatment with steroids or anti-epileptic medications
World Health Organization (WHO) grade IV glioma with definitive resection prior to consent, with residual radiographic contrast enhancing disease on the post-operative computed tomography (CT) or magnetic resonance imaging (MRI) of <  cm in maximal diameter in any axial plane
The ultrasound, magnetic resonance imaging (MRI), or computed tomography (CT) based volume estimation of the patients prostate gland should be =<  grams\r\n* For patients with prostate size >  grams cytoreduction therapy with ADT is recommended
Participants must have shown unequivocal evidence for tumor progression by magnetic resonance imaging (MRI) or computed tomography (CT) scan
Active or untreated central nervous system (CNS) metastases as determined by computed tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening and prior radiographic assessments
A diagnostic contrast-enhanced magnetic resonance imaging (MRI) or computed tomography (CT) scan of the brain must be performed preoperatively and postoperatively (preferably within  hours of surgery), prior to the initiation of radiotherapy
Imaging (computed tomography [CT] or magnetic resonance imaging [MRI]) =<  days of study registration negative for disease recurrence
Visceral metastases as assessed by chest, abdominal or pelvic computed tomography (CT) (or other imaging modality)
Active or untreated central nervous system (CNS) metastases as determined by computed tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening and prior radiographic assessments
Outpatients with histologically/cytologically documented or radiographically diagnosed unresectable hepatocellular carcinoma (HCC) who are candidates for systemic therapy and for whom a decision to treat with sorafenib has been made; radiographic diagnosis needs typical findings of HCC by a radiographic method, i.e. on multi-dimensional dynamic computed tomography (CT), CT hepatic arteriography (CTHA)/CT arterial portography (CTAP) or magnetic resonance imaging (MRI)
Active and untreated central nervous system (CNS) metastasis (including metastasis identified during screening magnetic resonance imaging [MRI] or contrast computed tomography [CT])
Phase Ib and II: surgical candidates, with moderate to high-risk pathologically-confirmed rectal cancer (stage cT-N or cT-N+); clinical staging by endoscopic ultrasound (EUS) or magnetic resonance imaging (MRI) is permitted
The patient must have post-operative contrast enhanced imaging (computed tomography [CT] or magnetic resonance imaging [MRI]) unless only biopsy performed (in which case post-operative imaging is not routinely obtained; in these patients, the preoperative study will serve as baseline
Prostate volume (by ultrasound [US], computed tomography [CT] or magnetic resonance imaging [MRI] measurement) <  cc at time of enrollment
Patients must have American Joint Committee on Cancer (AJCC) TNM tumor stage III, IV a, or IV b (with no evidence of distant metastases) as determined by imaging studies (performed <  days prior to registration) and complete neck exam from the skull base to the clavicles; the following imaging is required: computed tomography (CT) scan with IV contrast or magnetic resonance imaging (MRI); the primary tumor should be cT or T and cervical nodes cN, Na, or Nb based on clinical or radiographic criteria
Unequivocal evidence of tumor progression by magnetic resonance imaging (MRI) with and without contrast and with perfusion (or computed tomography [CT] if MRI is contraindicated); the scan must be performed within  days of starting treatment
Participants must have histologically or/and radiologically confirmed advanced hepatocellular carcinoma (HCC); radiographic diagnosis needs typical findings of HCC by radiographic method i.e. on multi-dimensional dynamic computed tomography (CT), CT hepatic arteriography (CTHA)/CT arterial portography (CTAP) or magnetic resonance imaging (MRI)
Imaging (computed tomography [CT] or magnetic resonance imaging [MRI]) evidence of hemorrhage deemed significant by the treating physician (> grade ); subjects with history of central nervous system (CNS) hemorrhage are not eligible
Radiographic evidence of spinal metastasis is required and may be obtained from radionuclide bone scans, computed tomography imaging, and magnetic resonance imaging; other studies may be used with principal investigator approval, but plain radiograph (X-ray) alone is not sufficient
If patients have small-volume disease the current study will be restricted to patients with minimal ascites not causing abdominal distention/mesenteric thickening or not requiring paracentesis, or lesions =<  cm by spiral computed tomography (CT) or magnetic resonance imaging (MRI) at baseline
Preoperative evaluation to rule-out extra-uterine disease may include computed tomography (CT) scan, magnetic resonance imaging (MRI), or ultrasound; preoperative imaging is not mandatory for study enrollment
Patients with known contraindication to magnetic resonance imaging (MRI), such as cardiac pacemaker, shrapnel, or ocular foreign body; however, head computed tomography (CT) with contrast is allowed in place of MRI at baseline and throughout the study if MRI is contraindicated and a participants CNS lesions are clearly measurable on the head CT
Histologically confirmed metastatic uveal melanoma in the liver; patients must have at least one untreated, or progressed liver metastasis that is >=  mm in longest diameter by spiral computed tomography (CT) scan or magnetic resonance imaging (MRI); the total volume of the tumors must be less than % of the liver volume
A brain scan should be performed within  days prior to registration and steroid dosing should be stable or decreasing for at least  days; if the steroid dose is increased between the date of imaging and registration a new baseline magnetic resonance (MR)/computed tomography (CT) is required; the same type of scan, i.e., magnetic resonance imaging (MRI) or CT must be used throughout the period of protocol treatment for tumor measurement
Primary disease > . cm in largest diameter as measured by computed tomography (CT) or magnetic resonance imaging (MRI)
Treated (surgery, radiation therapy) but not clinically and radiographically stable  weeks after local therapy(as assessed by contrast enhanced magnetic resonance imaging [MRI] or computed tomography [CT]), OR
Maximum tumor dimension of =<  cm in lymph nodes, soft tissue, osseous metastases, or spinal metastases seen on imaging (computed tomography [CT], magnetic resonance imaging [MRI] or PET/CT) and considered amenable for radiation therapy (RT)
All lung lesions must be visible on computed tomography (CT) imaging
Inability to have neither a magnetic resonance imaging (MRI) nor a computed tomography (CT) scan; patients with a pacemaker must undergo CT instead of MRI to be eligible
Clinically unstable central nervous system (CNS) metastases (to be eligible, subjects must have stable disease ?  months, confirmed by magnetic resonance imaging (MRI) or computed tomography (CT) scan, and/or have CNS metastases well controlled by low-dose steroids, anti-epileptics, or other symptom-relieving medications)
Prostate size as determined on magnetic resonance imaging (MRI) to be <  cc; prostate size can be determined on computed tomography (CT) scan if MRI is not available
Diagnosis of HCC by biopsy-proven pathologic diagnosis or by clinical criteria as defined below: \r\n* Clinical criteria to be met if patient has a history of cirrhosis or chronic hepatitis B infection:\r\n** Imaging abnormalities >  cm in size with classic enhancement by magnetic resonance imaging (MRI) or triple-phase computed tomography (CT) scan\r\n** Alpha-fetoprotein (AFP) of any value\r\n* Clinical criteria to be met if patient has no history of cirrhosis or chronic hepatitis B infection\r\n** Imaging abnormalities >  cm in size with classic enhancement by MRI or triple-phase CT scan\r\n** And AFP >  mg/dL
Patients with untreated central nervous system (CNS) metastases; patients should have a head CT/magnetic resonance imaging (MRI) within  days prior to treatment initiation; patients with previously excised/gamma knifed solitary or oligometastases and controlled disease are eligible
At least  node ?  cm on computed tomography (CT) or magnetic resonance imaging (MRI) or
Centrally located tumors with radiographic evidence (computed tomography [CT] or magnetic resonance imaging [MRI]) of local invasion of major blood vessels
Hypersplenism documented by imaging study (ultrasound [US] or computed tomography [CT])
Patients must have a patent portal vein as documented by computed tomography (CT), magnetic resonance imaging (MRI), or ultrasound
Imaging, a combination of at least two of the following (computed tomography [CT], magnetic resonance imaging [MRI], endoscopic ultrasound [EUS]) staging the pancreatic mass as locally advanced
Patients with clinically unstable central nervous system (CNS) metastasis (to be enrolled in the study, subjects must have confirmation of stable disease by magnetic resonance imaging [MRI] or computed tomography [CT] scan within  weeks of the first day of study defined treatment and have CNS metastases well controlled by steroids, anti-epileptics or other symptom-relieving medications)
Active or untreated central nervous system (CNS) metastases as determined by computed tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening or prior radiographic assessments. Participants with radiographically stable, asymptomatic, previously irradiated lesions are eligible provided participant is >/= weeks beyond completion of cranial irradiation and >/= weeks off of corticosteroid therapy
Patient with known but adequately treated brain metastases and without central nervous system (CNS) disease progression as determined by computed tomography (CT) or magnetic resonance imaging (MRI) imaging within  weeks of the first dose of study drug
Subjects with metastatic disease limited to bone are ineligible unless there is at least one lytic lesion with identifiable soft tissue components that can be evaluated by computed tomography (CT) or magnetic resonance imaging (MRI)
Magnetic resonance imaging (MRI) (or computed tomography [CT] if MRI is not available) of the brain must be performed within  days prior to study entry
Centrally located tumors with radiographic evidence (computed tomography [CT] or magnetic resonance imaging [MRI]) of local invasion of major blood vessels
Brain lesion(s), if still present, must be confirmed stable (i.e., no increase in lesion size) for >=  weeks prior to randomization (stability must be confirmed with two consecutive magnetic resonance image (MRI) or computed tomography (CT) scans with contrast, AND
Phlebotomy-dependent participants with splenomegaly by magnetic resonance imaging (MRI) or computerized tomography (CT) imaging (?  cubic centimeters [cm^]) or without splenomegaly (<  cm^, unpalpable, or prior splenectomy)
Patients must have shown unequivocal evidence for tumor recurrence or progression by magnetic resonance imaging (MRI) or computed tomography (CT) scan with contrast
Subject has no contraindication for computed tomography (CT) and/or magnetic resonance imaging (MRI) during screening and is able to complete a screening examination; CT and/or MRI within  months of screening is required
Patients must have a diagnostic quality magnetic resonance imaging (MRI) of the brain or if contraindicated then contrast computed tomography (CT) scan of the head performed within  days prior to registration
Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy, radiosurgery, or surgery and stable for at least  weeks prior to the initiation of study treatment; stability must be confirmed by magnetic resonance imaging (MRI) or computed tomography (CT) imaging and/or treating investigator determination
Centrally located tumors with radiographic evidence (computed tomography [CT] or magnetic resonance imaging [MRI]) of local invasion of major blood vessels
Active or untreated central nervous system (CNS) metastases as determined by Computed Tomography (CT) or magnetic resonance imaging (MRI) evaluation
Patients with known bone metastases, with evidence of corticol bone damage/lytric lesions/blastic lesions on standard imaging studies (computed tomography [CT]/magnetic resonance [MR])
Radiographic (X-ray, or computer tomography [CT]) evidence of at least  lytic bone lesion (or at least  focal lesion per magnetic resonance imaging [MRI])
Alpha feto protein (AFP) levels within normal institutional limits or judged to be not clinically significant by the investigator; Exception: If deemed clinically significant, then liver imaging must be available within previous  months (e.g., ultrasound, computed tomography [CT] scan, magnetic resonance imaging [MRI]) showing no evidence of hepatocellular carcinoma
Advanced chronic pancreatitis as determined by the following criteria: EUS score greater than , calcifications in combination with atrophy and/or dilation of >=  mm, or evidence of advanced chronic pancreatitis by computed tomography (CT) or magnetic resonance imaging (MRI) results in the past  months
Confirmed diagnosis of liver cirrhosis assessed by the presence of clinical signs, symptoms, body imaging (ultrasound, computed tomography [CT], or magnetic resonance imaging [MRI]), or liver biopsy
Have had an abdominal imaging test (CT, MRI, or ultrasound) within the past  months
Confirmed diagnosis of liver cirrhosis (Child-Pugh A or B) assessed by the presence of clinical signs, symptoms, body imaging (ultrasound, computed tomography [CT], or magnetic resonance imaging (MRI), or liver biopsy
Subjects with bone dominant disease with at least  skeletal metastases identified at baseline by bone scintigraphy and confirmed by computed tomography (CT)/magnetic resonance imaging (MRI).
Known active metastases to the brain, spinal cord or leptomeninges unless adequately treated with radiotherapy, radiosurgery, or surgery and stable for at least  weeks of first study treatment as documented by magnetic resonance imaging (MRI) or computed tomography (CT) imaging and having no ongoing requirement for steroids
Patients with untreated focal liver observations on liver ultrasound or multiphase contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) performed as part of clinical standard of care within  weeks before patient enrollment
Presence of at least one target liver or other intra-abdominal lesion detected by standard staging scans that, in the judgment of study investigators, would be amenable to hyperpolarized C- pyruvate/metabolic MR imaging:\r\n* Target lesion must measure >= . cm in long axis diameter on computed tomography (CT) or magnetic resonance imaging (MRI)
Have at least one kidney lesion identified but incompletely characterized on a non-contrasted ultrasound (US), computed tomography (CT), or magnetic resonance (MR) exam for which the patients provider recommends follow-up studies or further evaluation with an additional imaging tests.
PATIENT: Patients who have received any contrast medium (X-ray, magnetic resonance imaging [MRI], computed tomography [CT] or ultrasound [US]) in the  hours prior to the research US exam
For patients with organ confined renal tumors to be enrolled, the renal mass must be >=  cm in diameter on computed tomography (CT) or magnetic resonance imaging (MRI) and can be any clinical stage Ta-T (non-metastatic); a histologic diagnosis is not required for enrollment; the primary imaging site would be kidney
GROUPS , , AND : Group  participants identified as having IPMN on standard radiographic imaging that meets criteria for resection based on symptoms or on conventional imaging (computed tomography [CT] or MRI) findings
Measurable or evaluable disease, lesions that have not been previously radiated, with clinically indicated imaging evaluation performed within  weeks prior to study entry (computed tomography [CT], magnetic resonance imaging [MRI], fluorodeoxyglucose [FDG]-PET or bone scan); patients requiring concurrent radiation treatment are not eligible unless additional lesions that are not being irradiated and are assessable for targeting are present
A CXR (chest x-ray), liver enzymes, and a head and neck computed tomography (CT) or magnetic resonance imaging (MRI) and an ultrasound negative for clinical evidence of metastasis
Primary or recurrent/metastatic lesion size >= . cm as determined by imaging studies (ultrasonography, mammography, computed tomography [CT] or magnetic resonance imaging [MRI]) or physical examination
Patients who received anti-tumor therapy after histopathologic transformation to glioblastoma must have shown unequivocal radiographic evidence of tumor progression by contrast-enhanced magnetic resonance imaging (MRI) scan (or computed tomography [CT] scan if MRI is contraindicated)
Patients who have received any contrast medium (X-ray, magnetic resonance imaging [MRI], computed tomography [CT], of US) in the  hours prior to the research US exam
Be scheduled for contrast-enhanced magnetic resonance imaging (MRI)/computed tomography (CT) to monitoring of RCC recurrence as part of their , , , , or  month CT/MRI follow up
Patients must have radiographic evidence of upper tract urothelial cancer by computed tomography (CT), magnetic resonance imaging (MRI) or intravenous pyelogram (IVP) in order to undergo this procedure
The lesion shows intratumoral arterial phase enhancement on contrast enhanced computed tomography (CT) or magnetic resonance imaging (MRI)
Active or untreated central nervous system (CNS) metastases as determined by computed tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening and prior radiographic assessments
Central nervous system (CNS) lymphoma; active brain or leptomeningeal metastases, as indicated by positive cytology from lumbar puncture or computed tomography (CT) scan/magnetic resonance imaging (MRI).
Central nervous system (CNS) lymphoma; active brain or leptomeningeal metastases, as indicated by positive cytology from lumbar puncture or computed tomography (CT) scan/magnetic resonance imaging (MRI).
Active or untreated CNS metastases as determined by computed tomography (CT) or magnetic resonance imaging evaluation during screening and prior radiographic assessments